Skip to main content
Signal8

Stemtech Corp (STEK)

Stemtech Corporation is a pioneering company specializing in stem cell nutrition. It formulates scientifically-backed products designed to optimize the body's intrinsic stem cell physiology. With a market presence spanning the Americas, Latin America, and Asia, its offerings are engineered to bolster the natural functions of the body's stem cells. These solutions achieve this by stimulating the release of more stem cells, facilitating their efficient circulation through the bloodstream, and guiding their migration into various tissues. This process enables the stem cells to perform their continuous regenerative and repair tasks, crucial for maintaining optimal health and vitality. The company's comprehensive portfolio of dietary supplements includes prominent brands such as RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze. Stemtech Corporation's operations are headquartered in Miramar, Florida.

Sector: Wholesale-Drugs, Proprietaries & Druggists' Sundries

Industry: Drug Manufacturers - Specialty & Generic

Stemtech Corporation logo

Stemtech Corporation

OTC:STEKHealthcare
$0.0001
Mkt Cap$300K
EV-
Float2.7B
O/S3B
VOL1.5M sh
$ Vol$150
RVOL0.13×
Inst Own-
Net Cash/Sh-
Dilution
Short interest (FINRA)
Not computed: short interest % needs a single float figure, and the float on record is a bound or estimate.
Oct 30 (18d)
147
Oct 30 (18d)
1.00
Oct 30 (18d)
Borrow (IBKR)

The cost to borrow STEK shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
92.1%
Nov 16 (1d)prev 90.4%▲ 1.7 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

657.5K
Oct 29 (19d)prev 657.5K– 0.0%
Price, short interest & fails to deliver
Fails to deliver24 settlement dates
Latest fails to deliver
DateShares failed
Oct 29, 2026657.5K sh
Oct 28, 2026657.5K sh
Sep 30, 2026852.4K sh
Sep 29, 2026852.4K sh
Sep 23, 2026226.0K sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 16
Latest sessions
DateReported short
Nov 16, 202692.1%
Nov 13, 202690.4%
Nov 12, 202694.6%
Nov 11, 202625.8%
Nov 10, 202632.9%
81-session median 88.9%mean 73.3%range 0.0–100.0%

130 calendar days requested; 82 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for STEK: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 147 STEK shares were sold short (1.00 days to cover).